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Bioﬁlms deﬁne mono- or multispecies communities embedded in a self-produced protective matrix, which is strongly attached to
surfaces. They often are considered a general threat not only in industry but also in medicine. They constitute a permanent source
of contamination, and they can disturb the proper usage of the material onto which they develop. This paper relates to some of the
most recent approaches that have been elaborated to eradicate Candida bioﬁlms, based on the vast eﬀort put in ever-improving
models of bioﬁlm formation in vitro and in vivo, including novel ﬂow systems, high-throughput techniques and mucosal models.
Mixed bioﬁlms, sustaining antagonist or beneﬁcial cooperation between species, and their interplay with the host immune system
are also prevalent topics. Alternative strategies against bioﬁlms include the lock therapy and immunotherapy approaches, and
material coating and improvements. The host-bioﬁlm interactions are also discussed, together with their potential applications in
Candida bioﬁlm elimination.
1.Introduction
Bioﬁlms, adherent microbial communities embedded in a
polymer matrix, are common in nature. However, they are
alsoapersistentcauseofhygieneproblemsinthefoodindus-
tryandinthemedicalﬁeld[1].Bioﬁlmsresultfromanatural
tendency of microbes to attach to biotic or abiotic surfaces,
which can vary from mineral surfaces and mammalian
tissues to synthetic polymers and indwelling medical devices,
and to further grow on these substrates [2–4]. Candidiasis,
caused most frequently by Candida albicans,a n dt oal e s s e r
extent by C. glabrata, C. tropicalis, or C. parapsilosis,i so f t e n
associated with the formation of bioﬁlms on the surface
of medical devices and tissues [5]. Candida albicans is a
dimorphic fungus and is part of the commensal human
micoﬂora. It is also an opportunistic pathogen of the human
body when its proliferation is not controlled by the host
immune system. It is one of the most often identiﬁed agents
in nosocomial infections and is capable of invading virtually
any site of the human host, from deep tissues and organs, to
superﬁcial sites such as skin and nails, to medical implants
and catheters [6]. C. albicans bioﬁlm development has been
characterized in various model systems both in vitro and in
vivo [7–9] and consists of distinct phases. The initial step
consists of the adhesion of fungal cells of the yeast form to
the substrate. It is followed by a phase of cell ﬁlamentation
and proliferation, which results in the formation of multiple
layers of sessile cells of diﬀerent morphologies, including
pseudohyphal and hyphal cells. The next step of maturation
results in a complex network of cellsembedded in extracellu-
larpolymericmaterial,composedofcarbohydrates,proteins,
hexosamine, phosphorus and uronic acid, as well as host
constituentsinnaturalsettings[10].Thereisindeedevidence
that host glycoproteins, nucleic acids, and cells, such as
neutrophils, may participate in the maturity of the matrix,
in particular on mucosal sites [11–13]. The establishment
of the bioﬁlm extracellular matrix (ECM) represents a
unique characteristic of bioﬁlms. Quantity and composition
of the matrix vary from one species to another and in
diﬀerent sites of infection depending on environmental cues,2 International Journal of Microbiology
Table 1: Examples of Candida bioﬁlm models in vitro.
Models in vitro Device Used for
Closed systems (discontinuous growth
conditions over time (nutrient depletion,
accumulation of secondary metabolites))
(i) 96-well polystyrene microtiter plate
(ii) Discs/pieces of catheter in 6- to
24-well plate (discs made of silicone,
polyurethane, polycarbonate, polystyrene,
stainless steel, Teﬂon, polyvinyl chloride,
hydroxyapatite, and porcelain)
Easy and widespread use: comparative analyses
between strains and species [33–39] to antifungal
susceptibility tests [40]
(iii) Calgary bioﬁlm device (80 pegs
immersed into a standard 96-well plate)
Bioﬁlm formation studies by diﬀerent Candida
species [41]
(iv) Candida bioﬁlm chip (several
hundreds nanobioﬁlms encapsulated in
collagen and formed on a glass slide
treated to obtained a monolayer of
hydrophobic coating)
High-throughput bioﬁlm studies [42]
Flow systems (Continuous growth
conditions)
(i) CDC bioﬁlm reactor (24 bioﬁlms can
be formed simultaneously)
Comparative analysis of bioﬁlm quantiﬁcation
methods [43]
(ii) Microfermentors (bioﬁlms formed on
a Thermanox slide glued to a glass spatula) Gene expression analyses [44]
(iii) Modiﬁed Robbins device (adapted to
hold several individual discs)
Study of the eﬀects of shear forces and nutrient
supplies on C. albicans bioﬁlm formation [45]
(iv) Flow bioﬁlm model (silicone
elastomer strip placed into a
polypropylene conical tube)
Study of C. albicans bioﬁlm development,
architecture, and drug resistance [46]
Shear stress conditions
Rotating disc system (silicone catheter
devices placed under a shear force of 350
revolutions per minute)
C. albicans bioﬁlm architecture and development
[47]
such as nutrient availability and mechanical stimuli [14–
17]. Matrix synthesis by Candida bioﬁlm cells has been
shown to be minimal in static conditions in comparison to
dynamic environments [10], aggravating bioﬁlm formation
on mucosal and abiotic sites where there is a ﬂuid ﬂow,
such as on the oral mucosa, the urethra, or central venous
catheters. The last step, dispersion of cells from a bioﬁlm,
plays a key part in the bioﬁlm developmental cycle as it
is associated with candidemia and disseminated invasive
disease [18].
Pathogenic microbes that build bioﬁlms are potential
causes of constant infections that defy the immune system
and resist antimicrobial treatment, partly due to the matrix-
inherent limited exposure of the cells within a bioﬁlm to
these types of immunological and medical arsenals [19–
22]. Other mechanisms of bioﬁlm resistance have been
suggested, such as slow growth, diﬀerential regulation of
the cell metabolic activity caused by nutrient limitation and
stress conditions, and cell density [23–25]. In addition, the
ability to adhere, as a unique prerequisite to form a bioﬁlm,
is a fast process, which makes the prevention of bioﬁlm
development diﬃcult with the current antimicrobial tools
and strategies.
Bioﬁlms are diverse communities and therefore vary
depending on the microbe, the surface, and the colonization
niche [5, 26–30]. This paper gives an update on the recent
eﬀorts made in establishing alternative means of eradication
and also prevention of Candida spp. bioﬁlms, by developing
new models of bioﬁlm formation in ﬂow conditions, as
well as high-throughput rapid screening analyses in vitro.
Newly developed in vivo models anticipate a shift of interest
towards mixed fungal-bacterial bioﬁlms and their role in
pathogenesis in mucosal infections in particular. Keeping
in mind that there is no unique model representative of
all bioﬁlms, it remains quite a challenge to tackle bioﬁlm
inhibition. One of the most attractive perspectives is the
developmentofantimicrobematerials,andthelatestﬁndings
are presented here.
2.Candida Bioﬁlm Models
2.1.ModelsInVitro. Bioﬁlmformationisamultistepgrowth
behaviour that results from complex physical, chemical, and
biological processes [31, 32]. Because of the versatility of the
milieu in which Candida bioﬁlms can develop in the human
host, from the oral cavity contributing to dental plaque
formation to the blood stream in intravenous catheters and
the urinary tract, it seemed necessary to reproduce in vitro
as many conditions as possible to establish common and
speciﬁc characteristics of Candida bioﬁlm formation. In that
respect, a multitude of in vitro studies has been described
that relates to the impact of diﬀerent types of substrate,
nutritional supplies, in ﬂow or static conditions, on adhesion
and bioﬁlm properties of several Candida species, and recent
ﬁndings are presented next. An overview of the in vitro
models available to study Candida bioﬁlms is provided in
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2.1.1. Candida Species and Substrates Speciﬁcities. While
bioﬁlm formation is a general characteristic of many
microbes, bioﬁlm features such as architecture, matrix
composition, and resistance to antifungal drugs are species
and substrate dependent. And examples that demonstrate
variation in bioﬁlm ability and structure are numerous.
Some studies are discussed below, and in particular studies
related to Candida bioﬁlms formed on dental materials.
Interest has indeed grown in investigating the role of
Candida species and the eﬀect of the type of material in
the development of denture stomatitis [48]. For example,
in a comparative study, cell counts analyses showed that
saliva-coated discs harboured less C. glabrata cells than
untreated discs, while the number of C. albicans cells was
not aﬀected by the saliva coating [33]. However, both species
adhered better on hydroxyapatite (HA) surface than on two
other types of dental material, polymethylmetacrylate and
soft denture liner. Surprisingly, dual species experiments
showed that C. glabrata displayed higher cell counts when
g r o w ni nt h ep r e s e n c eo fC. albicans than when grown
alone.Incontrast,hyphaldevelopmentbyC.albicansseemed
to be reduced in the presence of C. glabrata in most of
the conditions tested. These data may help understand the
impact that Candida species may have on each other, as
mixed species communities are being identiﬁed in clinical
samples [49]. In another case study, using discs as support
for bioﬁlm formation in vitro, HA substrate appeared to
be less prone to Candida adherence than acrylic denture,
porcelain, or polystyrene when not coated with saliva [34].
In addition, the eﬀect of serum and similar materials on
bioﬁlm development of C. albicans clinical isolates was also
evaluated in vitro [35]. Disc coupons made of polycar-
bonate, polystyrene, stainless steel, polytetraﬂuoroethylene
(also known as Teﬂon), polyvinyl chloride (PVC), or HA
were used in a high throughput assay. For all surfaces
tested, the presence of serum increased bioﬁlm formation.
However, in absence of serum, Teﬂon supported higher
bioﬁlm production than any other material, likely due to its
high roughness and hydrophobicity properties.
The diﬀerential ability to form bioﬁlm of 84 strains from
several Candida species, including C. albicans, C. glabrata,
C. krusei, C. tropicalis,a n dC. parapsilosis, was assessed on
clinical materials, such as Teﬂon and PVC. All species, with
the exception of Candida glabrata, favoured Teﬂon [50].
In this study, C. glabrata together with C. krusei strains
were not highly proﬁcient in forming dense bioﬁlms, as
quantiﬁedbycolony-formingunits.Moreover,C.parapsilosis
strains showed the least uniformity in the ability to form
bioﬁlm, followed by C. tropicalis and C. albicans. While some
variability in the ability to form bioﬁlms between strains
of C. albicans has been documented in vitro, a study by
M a c C a l l u me ta l .[ 51] revealed that bioﬁlm formation in
vitro did not signiﬁcantly vary between strains of the four
major clades of C. albicans, classiﬁed according to single-
nucleotide polymorphisms determinations and analysis of
DNA repeat sequences [52]. However, high variation in the
ability to form bioﬁlm among strains of C. parapsilosis and
less extensive bioﬁlm formation by C. glabrata specimens has
been illustrated in a few studies by crystal violet staining
and confocal laser scanning microscopy [36–38]. Strain-
dependent variation in bioﬁlm formation was also observed
among isolates of two genetically nonidentical classes of
C. parapsilosis,n a m e l y ,C. orthopsilosis and C. metapsilosis
[39, 53]. All three species could form bioﬁlms, but metabolic
activity of bioﬁlm cells diﬀered between strains of the same
species. However, conﬂicting data with diﬀerent isolates
reported the inability of C. orthopsilosis and C. metapsilosis to
form bioﬁlm in polystyrene 96-well plate assay in vitro [54,
55]. Bioﬁlm formation among C. parapsilosis sensu strictu
strains was also found to vary according to the geographical
regions and the body sites from which the isolates came from
[56]. Isolates from blood and cerebrospinal ﬂuid seemed
more prone to form bioﬁlms than isolates from nails,
catheters, and mucosa. Overall, these data suggest a high
variability in bioﬁlm ability of strains of C. parapsilosis and
related species, perhaps due to inadequate models or to an
intrinsic poor ability to establish the bioﬁlm growth by these
species.
In a Calgary bioﬁlm model adapted to Candida spp., C.
kruseidevelopedthelargestbioﬁlmmassincomparisontoC.
albicans, C. glabrata, C. dubliensis, and C. tropicalis [41]. This
model, allowing 80 bioﬁlms to be formed at once, seemed
to be very favourable to C. krusei bioﬁlm development as
bioﬁlms of that species constituted of thick multilayered
structures composed of pseudohyphal cells, while the other
species formed sparse bioﬁlms.
In a last example of novel in vitro models of bioﬁlm
formation on various soft contact lenses, analyses revealed
diﬀerences in hyphal content and architecture of the fungal
keratitiscausativeagentsFusariumandC.albicans[57].Poly-
mers such as balaﬁlcon A and galyﬁlcon A were favourable to
ﬁlamentous growth of C. albicans, while others such as etaﬁl-
con A and lotraﬁlcon A sustained bioﬁlms formed mainly
of yeast cells. In addition, diﬀerences in bioﬁlm formation
were also observed between peripheral and central regions of
the lenses, with dense bioﬁlms formed preferentially in the
centres of the lenses. Although a direct relationship between
the lens ionic charge and water content and the ability of
fungi to form bioﬁlm could not be established, these data
conﬁrm previous ﬁndings that irregular surface texture of
materials aﬀect both cellular morphology and bioﬁlm mass
[58].
2.1.2. Synthetic Media and Flow Systems Mimicking In Vivo
Conditions. The physiological speciﬁcity of infection sites
is also an important factor, and eﬀorts have been made
to reproduce some major environmental cues in vitro,
such as mimicking the blood ﬂow or the urine. Bioﬁlms
grown in synthetic urine medium were comparable to
those grown in the commonly used cell culture RPMI
medium [59]. And time course studies revealed that the
development of both types of bioﬁlm followed a similar
pattern, with an initial adherence phase, followed by growth,
proliferation, and maturation. The bioﬁlms diﬀered slightly
in their architecture, as bioﬁlms grown in synthetic urine
medium seemed to be less complex and less dense, with a
larger proportion of yeast cells rather than elongated cells.
Increased nutritional supply promoted bioﬁlm formation in4 International Journal of Microbiology
another model of artiﬁcial urine medium, highlighting once
again the importance of reproducing as closely as possible
the physiological conditions to gain relevant information
[60]. C. tropicalis bioﬁlms were also characterized in artiﬁcial
urine medium, on urinary catheters in a ﬂow model [61].
Cells were able to colonize the catheters in the presence of
the artiﬁcial urine medium and to detach from these silicone
catheters, illustrating their capacity to colonize distal sites.
Bioﬁlms grown in static conditions have been pre-
dominantly studied, in comparison to ﬂow-based systems,
due to a low cost, a rapid processing of large number of
samples, and limited technical requirements. However, in
order to maintain their niches in dynamic environments,
bioﬁlmsinvivoendureshearforcesgeneratedbytheconstant
ﬂow of physiological ﬂuids [62]. Gene expression analyses
revealed only a marginal diﬀerence between bioﬁlms grown
in static conditions, such as microtiter plates or serum-
treated catheters, and those grown in a ﬂow system in
microfermentors [44]. Interestingly, the bioﬁlm transcrip-
t o m e sw e r en o ts t r o n g l ya ﬀected by factors such as nutrient
ﬂow and aerobiosis, in contrast to the gene expression
of free-living cells. However, a few studies indicated that
bioﬁlms grown under ﬂow conditions, in CDC reactors
or modiﬁed Robbins devices, contain more extracellular
matrix and more biomass [10, 43, 45]. Mature bioﬁlms
formed in a ﬂow of replenishing nutrients consist of a dense
network of yeast cells, pseudohyphae, and hyphal cells. In a
simple ﬂow model, using a silicone strip placed in a conical
tube, C. albicans bioﬁlms grew thicker than bioﬁlms grown
in static conditions, and grew faster as an 8-hour-grown
ﬂow bioﬁlm had similar biomass as a 24-hour-grown static
bioﬁlm [46]. The authors speculated that uninterrupted
food supply prohibited adverse conditions, such as nutrient
starvation and toxic accumulation, and hence promoted
rapid cell proliferation. A parallel study, using a rotating disc
system (RDS) to impose shear forces at physiological levels
to bioﬁlms developed on catheter pieces, illustrated similar
results as bioﬁlms under shear stress grew thinner but denser
than those in no-ﬂow conditions [47]. In the RDS model,
less cells adhered at ﬁrst, but by 24h bioﬁlms displayed
similar metabolic activity and dry weight as those obtained
in the static model. Suggestions that explained the increased
growth rate in shear conditions included an increased rate
of maturation in these conditions and a natural selection of
more robust cells capable of withstanding the ﬂuid friction
by growing faster.
2.1.3. High-Throughput Bioﬁlm Models. Another important
aspect of in vitro bioﬁlm modelling is the development of
high-throughput systems of particular interest in the large-
scale screening of antibioﬁlm molecules. Most studies so far
have made use of the 96-well microtiter plate assay [40].
In this model, bioﬁlms are formed directly on the bottom
of the wells, and the quantiﬁcation method is based on
the ability of sessile living cells to reduce tetrazolium salt
(XTT) to water-soluble orange formazan compounds. In an
eﬀort to upscale bioﬁlm production, a C. albicans bioﬁlm
chip system (CaBChip) has recently been developed by
Srinivasan et al. [42]. The high-density microarray platform
is composed of more than 700 independent and uniform
nanobioﬁlms encapsulated in a collagen matrix and provides
the ﬁrst miniature bioﬁlm model for C. albicans. Despite the
several-thousand-fold miniaturization, the bioﬁlms formed
on the chip displayed phenotypic characteristics, such as
a multilayer of yeast, pseudohyphae and hyphal cells, and
a high level of antifungal drug resistance, consistent with
those of bioﬁlms formed by standard methods. However,
echinocandins were not proﬁcient to eradicate bioﬁlm in
this system, potentially due to their binding to the collagen
matrix. In a second generation of the bioﬁlm chip, other
nonprotein matrices will be investigated. While this system
steps-up the number of bioﬁlms that can be produced at
once in static conditions, the next step may be to develop
high-throughput ﬂow bioﬁlm systems adapted to Candida
spp. Such a tool has been described based on a device
comprised of microﬂuidic channels that provide ﬂuid ﬂow
to 96 individual bacterial bioﬁlms [63]. The eﬀects of
antimicrobial agents on the bioﬁlms were rapidly screened,
and viability was quantiﬁed by ﬂuorescence measurements.
These high-throughput techniques will certainly contribute
greatly to the discovery of novel antibioﬁlm molecules.
2.2. In Vivo Models of Candida Bioﬁlms
2.2.1. Bioﬁlm Models on Inert Substrates. In vivo models are
undisputedly required to appreciate the hostile environment
that conditions bioﬁlm formation (Table 2). A few Candida
bioﬁlmmodels,mostlyassociatedtocatheterinfections,have
been developed in several rodents, giving insights on the in
vivo bioﬁlm structure and the eﬃcacy of various antifungal
agents [70]. The catheter-related in vivo bioﬁlm models
resulted in bioﬁlm formation within 24h and consisted of
complex structures of yeast and elongated cells embedded
in extracellular matrix, similar to those observed in in vitro
modelsystems[8].Whilesusceptibilitytoazoleswasreduced
in these models, liposomal amphotericin B lock therapy
and treatment with caspofungin or chitosan proved to be
eﬃcient against in vivo bioﬁlms [64, 65, 71]. Central venous
catheter models (CVCs) are also useful for the investigation
of the kinetics and occurrence of dissemination of the
microorganisms to other organs, demonstrated by colonisa-
tion by C. albicans of the kidneys in the rat model [8]. In
addition,thedevelopmentofaCVCmodelinmicewillallow
comparison to other modes of infection, in particular to the
commonly used disseminated candidiasis by tail vein infec-
tion. A murine model for catheter-associated candiduria
was recently developed and illustrated the role of Candida
bioﬁlms in the persistence of the urinary tract infection
[66]. It also outlined diﬀerences between murine and human
catheter-relatedcandiduriaintermsofbladderinﬂammation
and fungal burden in the urine. In another catheter-related
Candida-associated infection model, we developed a sub-
cutaneous foreign body system suitable for C. albicans [9].
This model, of nondisseminated nature, allowed the study
of bioﬁlm development for long periods of time (Figure 1)
but required the use of immunosuppression treatment of the
animals due to the high inﬂammatory response associated
with implant of foreign devices. However, eﬃcacy of theInternational Journal of Microbiology 5
Table 2: Candida bioﬁlms in vivo models.
Models in vivo Device Developed in
Catheter-associated models
(i) Central venous system Rat [8], rabbit [64], mouse [65]
(ii) Candiduria model Mouse [66]
(iii) Subcutaneous foreign body system
(bioﬁlms developed after 2 to 6 days in
infected implated catheter fragments)
Rat (immunosuppressed before and during
bioﬁlm development) [9]
Candida-associated denture stomatitis
models
(i) Acrylic denture material attached to
the hard palate (bioﬁlms developed
between the hard palate and the device)
Rat (immunosuppressed on day of infection)
[67]
(ii) Custom ﬁtted denture system (cast
fabrication of a ﬁxed part that is attached
to the posterior palate and a removable
part ﬁtted to the anterior palate)
Rat [68]
Mucosal model of oropharyngeal candidiasis
Bioﬁlms developed on the tongue after
infection by swabbing and drinking water
contaminated with Candida cells
Mouse (immunosuppressed on day of infection)
[12]
Vaginitis model In vivo and ex vivo models Mouse (treated with estradiol prior infection)
[69]
30μm 500μm
y
h
b
hc lw
Figure 1: Scanning electron microscopy images of wild type
Candida albicans bioﬁlms developed in vivo in the denture model
(left panel) and in the subcutaneous model (right panel). Elements
such as hyphal cells (h), yeast cells (y), bacterial cells (b), host cells
(hc) and catheter lumen wall (lw) are highlighted. Images were
adapted from the work of Nett et al. [67], and S. Kuchar´ ıkov´ aa n dP .
Van Dijck (MCB Laboratory, VIB, K.U. Leuven, unpublished data),
respectively.
echinocandin anidulafungin, by intraperitoneal injections,
was demonstrated against C. albicans bioﬁlm in this in vivo
system [72]. These in vivo models are all suited for further
study of novel antifungal therapies and for the use of novel
material technologies, including less adherent surfaces and
materialcoatingwithﬁxedorreleasingantifungalagents(see
the next section).
A relatively cost- and time-eﬀective Candida bioﬁlm
model on acrylic denture material, which does not require
the ex vivo mold process, was illustrated recently [67]. In this
rat model, bioﬁlms developed between the hard palate and
the denture material, following Candida inoculation in that
1mmspace(Figure 1). Fungal invasion of the palate and the
tongue and neutrophils inﬁltration also occurred, indicating
that the model was consistent with that of acute human
denturestomatitis.Interestingly,thedenturemodeloﬀersthe
possibility to study mixed bioﬁlm structure and behaviour
in response to antimicrobial treatments, as the bioﬁlms were
composed of both bacterial and fungal cells. Finally, bioﬁlms
developed on the denture model were inherently resistant to
ﬂuconazole, in accordance with previous ﬁndings [8, 72],
but also to the echinocandin micafungin, in contrast with
previous investigations performed in a diﬀerent model [73].
A plausible explanation suggested by the authors is that
the mixed bioﬁlm nature combined with the speciﬁc site
of infection, the oral cavity, is the cause of that antifungal
resistance. An alternative rat model of Candida-associated
denture stomatitis recently described diﬀers by the use of
animal-ﬁtted devices [68]. In this system, a removable part
of the device makes the replacement of the infected device
a relatively easy step. These models promise to deliver an
alternative mean of testing novel antibioﬁlm molecules.
2.2.2. Bioﬁlm Models on Biotic Surfaces. Tools and models to
study bioﬁlm formation developed on implanted materials
are numerous and indicative of the increased medicinal use
of such implants. Bioﬁlms formed on live surfaces are much
less characterized, yet they are recognized as causing or
aggravating numerous chronic diseases [74]. Besides dental
plaques, few reports have investigated bioﬁlm development
in clinical samples. Biotic bioﬁlms are poorly understood
as tissue samples are sparse and not easily accessible. The
oral cavity is an accessible in vivo model for studying
protein-surface interactions and has been well characterized
for bacterial bioﬁlm [75]. A mucosal model of oropha-
ryngeal candidiasis was recently proposed to characterise
C. albicans mucosal bioﬁlms in situ in mice [12]. Keratin,
originating from desquamating epithelial cells, constituted
a large proportion of the bioﬁlm matrix. First evidence
was given that epithelial cells, neutrophils, and commensal
oral bacteria co-exist within the fungal mucosal bioﬁlm
developed on mouse tongue. Bacteria were mostly found on
the apical part of the bioﬁlm, and very few were seen to6 International Journal of Microbiology
invade the tongue epithelium layer. This model highlights
the complexity of mucosal bioﬁlms, as host elements and
commensal organisms contribute in an active or passive
manner to the structure of the bioﬁlms.
C. albicans can also form bioﬁlms on the vaginal mu-
cosa, illustrated by two in vivo and ex vivo models in
immunocompetent estradiol-treated mice [69]. C. albicans
vaginalbioﬁlmsconsistedofyeastandhyphalcellsembedded
in extracellular material, illustrated by ConA staining of
the interspersed matrix. In the ex vivo model using vaginal
explants, no exogenous nutrients were provided, yet bioﬁlms
were formed most likely by scavenging host nutrients.
Host-pathogen interactions in bioﬁlm settings have
not yet been elucidated, but comparison between these
models promises to identify model-speciﬁc fungal and host
elements.
2.3. Mixed Species Candida Bioﬁlms. The relative contribu-
tion and the role of bacteria-Candida interactions in the
pathogenesis of mucosal infections are yet to be established.
However, there is clear evidence that multimicrobial interac-
tionshaveacentralroleinthecontextofhumandisease[76].
For example, microbial diversity was illustrated in a bioﬁlm-
related infection of the urinary tract [77]. Out of 535 clinical
samples of urinary catheters, Candida spp. were identiﬁed
amongthe39diﬀerentmicrobialtaxaisolated.Single-species
samples represented 12.5% only. C. albicans was isolated
in 141 samples, and other Candida species were present in
other 82 samples. Bioﬁlm formation ability of each isolated
strain was quantiﬁed in vitro, yet not in an artiﬁcial urine
medium, and cut-oﬀ values were used to deﬁne no, weak,
intermediate, and strong bioﬁlm producers. C. tropicalis
isolates were the strongest bioﬁlm producers among the
Candida species. Certain species of bacteria did not show
bioﬁlm formation ability in this study. These data illustrates
the fact that, in multispecies bioﬁlms, some have a great
potential to cause bioﬁlm-based infections, while others may
be more passive members of the structured community.
Commensalism, mutual cooperation, and antagonism make
the interactions within mixed bioﬁlms complex [78, 79]. A
summary of bacteria-Candida interactions and their eﬀect
on fungal development is provided in Table 3.B a c t e r i ac a n
interact with C. albicans cells within mixed bioﬁlms, and
in particular with hyphal cells. The methicillin-resistant
Gram-positive Staphylococcus aureus had the highest hyphal
association, in comparison to S. epidermidis, Strepococcus
pyogenes, Pseudomonas aeruginosa, Bacillus subtilis, and
Escherichia coli in decreasing order, respectively [80]. How-
ever, interaction between S. aureus and C. albicans did not
resultinreducedoralteredbioﬁlmviability.Inanotherstudy,
addition of bacteria to preformed Candida bioﬁlms in vitro
had an antagonistic eﬀect on bioﬁlm cell mass, often in
a cell-density-dependent manner [81]. With all inoculums
tested, P. aeruginosa reduced signiﬁcantly the fungal bioﬁlm
mass when added during the ﬁrst few hours of bioﬁlm
development. In a diﬀerent experimental assay, preformed
bacterial bioﬁlms signiﬁcantly reduced adhesion and bioﬁlm
growth of C. albicans [82]. Moreover, simultaneous addition
ofbacteriaandC.albicanscellsshowedthatinallcasesfungal
adhesion was decreased, whereas bacterial biomasses were
not aﬀected.
Hypotheses of synergistic relationships between mi-
crobes have been suggested, and in particular within mixed
bioﬁlm communities [83]. For example, bacterial adhesion
was observed on the tongue mucosa of C. albicans-infected
animals but not of noninfected animals, in a mucosal model
of oropharyngeal candidiasis [12]. Synergistic cooperation
can also perturb susceptibility to antimicrobial treatment.
For example, S. aureus resistance to vancomycin was
enhanced in mixed bioﬁlms with viable C. albicans cells,
whereas susceptibility of the fungal cells to the antifungal
amphotericin B was not altered [84]. Binding of the fungus
to the bacterial cells occurs via the Candida-speciﬁc adhesin
proteins, including Als3, Eap1, and Hwp1, as demonstrated
by heterologous expression of these cell wall proteins in
the model yeast Saccharomyces cerevisiae [85]. The role of
adhesins in single- and multispecies bioﬁlm formation is not
discussed here but can be found in previous reports [86–88].
3. Antibioﬁlm Strategies:
Research andDevelopment
Thecurrenttherapiesagainstfungaldiseases[96],employing
one of the ﬁve classes of antifungals (polyenes, pyrimidine
analogues, allylamines, azoles, and echinocandins) adminis-
trated orally or intravenously, are not discussed in this paper.
Each antifungal compound has advantages and limitations
related to its spectrum of activity and mode of action. The
susceptibility of Candida bioﬁlms to the current therapeutic
agents remains low, with the exception of the echinocandins
[97, 98]. However, these compounds have been employed
in diﬀerent approaches, such as lock therapy or material
coating as releasing agent. These alternative methods and
their perspective of usage are discussed below.
3.1. Lock Therapy Approach and Prevention against Catheter-
Related Blood Stream Infections. Nosocomial infections asso-
ciated with medical devices represent a large proportion of
all cases of hospital-acquired infections [99]. In particular,
insertion of any vascular catheter can result in a catheter-
related infection, as microorganisms can colonise catheter
external and internal surfaces. Some of the favourite niches
of colonisation of Candida spp. include indeed vascular and
urinary catheters and ventricular assist devices, which can
be accompanied with high mortality rates [100]. Adherence
to the catheter surface, facilitated by host proteins such
as ﬁbronectin and ﬁbrinogen, can then lead to bioﬁlm
formation [101]. The antimycotic lock therapy approach is
currently recommended and employed in treating catheter-
related bloodstream infections (CRBSI), in particular for
long-term catheters, according to the Infectious Diseases
Society of America guidelines [102]. However, lock thera-
peutic treatment is pathogen– speciﬁc as catheter removal
is recommended for CRBSI caused by Candida species
and Staphylococcus aureus. The lock therapy involves the
instillation of high doses of an antimicrobial agent (from
100- to 1000-fold the minimal inhibitory concentration,International Journal of Microbiology 7
Table 3: Interspecies relationship with Candida spp. growth and bioﬁlm development.
Bacterial species Eﬀect on C. albicans hyphal growth Eﬀect on Candida bioﬁlm
Staphylococcus aureus (+) Associates to hyphal cells (56%) [80] No antagonistic eﬀect in dual bioﬁlms with
C. albicans (BacLight LIVE/DEAD assay) [80]
Staphylococcus epidermidis (+) Associates to hyphal cells (25%) [80] Reduced adhesion and bioﬁlm formation by
a glycocalyx producer strain (CFU counts) [82]
Streptococcus pyogenes (+) Associates to hyphal cells (25%) [80]
Streptococcus mutans and
Streptococcus intermedius S. mutans inhibits hyphal formation [89, 90]
No signiﬁcant eﬀect on bioﬁlm viability at densities
ranging from 6.25·105 to 1·107 cells/mL (bacteria
added to preformed 3-hour-old bioﬁlms;
polystyrene in vitro model; CFUs analyses) [81]
Streptococcus gordonii ( + ) S t i m u l a t e sh y p h a lg r o w t h[ 91] Promotes mixed bioﬁlms with C. albicans [91]
Pseudomonas aeruginosa (−)
(i) Associates to hyphal cells (17%) [80]
( i i )R e d u c e dh y p h a lg r o w t hi nC. albicans-P.
aeruginosa dual bioﬁlms [81]
(iii) Binds hyphae and kill C. albicans [92]
(i) Reduced adhesion and bioﬁlm formation by a
nonglycocalyx producer strain (CFU counts) [82]
(ii) Reduction of bioﬁlm mass ranging from 40% to
80% in a density-dependent manner [90]
(iii) Mutual bioﬁlm inhibition between Pa and
C. albicans, C. krusei and C. glabrata; decreased
bioﬁlm formation of C. parapsilosis and C. tropicalis
in presence of Pa; increased CFUs of Pa in presence
of C. tropicalis [93]
Escherichia coli (−) Associates to hyphal cells (5.7%) [80]
(i) Reduction of bioﬁlm mass ranging from 50% to
80% [81]
(ii) Mutual decrease in bioﬁlm cell mass between Ec
and C. albicans; inhibition of bioﬁlm development
by C. tropicalis, C. parapsilosis, C. krusei, and C.
dubliniensis; increased Ec cell numbers within C.
tropicalis and C. dubliniensis bioﬁlms [94]
Lactobacillus acidophilus Inhibition of viable bioﬁlm cell mass by 40% [81]
Bacillus subtilis Associates to hyphal cells (2.5%) [80]
Actinomyces israelii (+) Some inhibition of bioﬁlm at high densities [81]
Prevotella nigrescens and
Porphyromonas gingivalis
Inhibition of C. albicans hyphal development
[95]
Reduction of C. albicans bioﬁlms, only at high
densities [81]
Klebsiella pneumoniae, Serratia
marcescens, and Enterobacter
cloacae
Decreased bioﬁlm formation (CFU counts) [82]
(MIC)) directly into the catheter in order to “lock” it for a
certain period of time (from hours to days) [103].
Few reports are currently available on the usage of
antifungal lock solutions in clinical practice, but they seem
to indicate the curative eﬀect of this kind of treatment
[104, 105]. In vitro studies are more prevalent at the moment
and seem to also favour the use of antifungal lock therapy
to eliminate Candida spp. bioﬁlms, and in particular with
the usage of echinocandins [106]. For example, bioﬁlm
metabolic activity formed on silicone by C. albicans and
C. glabrata could be eﬀectively reduced by a 12h lock
treatment with micafungin (at 100–500x MIC), which was
shown to persist for up to 3 days [107]. Caspofungin
had an intermediate eﬀectiveness in the same study, as its
activity did not persist as long against C. glabrata bioﬁlms.
While these results are promising for potential use of the
lock technique to treat infected catheters, 100% bioﬁlm
inhibition could not be achieved. Sterilization of catheters
was obtained in vivo by lock treatment with amphotericin
B lipid complex (ABLC) in a rabbit model of catheter-
associated C. albicans bioﬁlm [108]. However, in this study,
the lock solution was administrated a few hours a day for
a prolonged period of time (7 days). Synergistic antibioﬁlm
combinations, used as lock solutions, between classical
antimicrobial agents and other compounds such as the
mucolytic agent N-acetylcysteine, ethanol, or the chelating
agent EDTA, are also eﬀective against S. epidermidis and C.
albicans individual and mixed bioﬁlms [109]. In a similar
approach, recent results suggest that the combination of
antibacterial agents with Gram-positive activity, including
doxycycline and tigecycline, with known antifungals, such
as AMB, caspofungin, and ﬂuconazole, can be useful for the
treatment of C. albicans bioﬁlms [110, 111].
The prevention of CRBSI has also been the focus
of research and randomized controlled trials [112]. In a
systematic assessment, Hockenhull et al. [113] showed the
clinical eﬀectiveness of CVCs treated with anti-infective
agents (AI-CVC) in preventing CRBSI. While trials are
still required to determine the most cost and clinical-
eﬀective anti-infective product, the routine usage of AI-CVC8 International Journal of Microbiology
will often be limited if appropriate use of other practical
care behaviour is not employed in intensive care units.
Antifungal impregnated CVCs have been tested in animal
models. The echinocandin caspofungin was employed to
prevent C. albicans bioﬁlm formation in a bioﬁlm model
in mice. C. albicans bioﬁlm formation was greatly reduced
in CVCs that had been pretreated for 24h with high
doses of caspofungin. The dissemination to the kidneys was
also reduced by such therapy [65]. Similarly, the use of
chitosan, a polymer isolated from crustacean exoskeletons,
as a pretreatment of catheters to prevent C. albicans bioﬁlm
formationwasvalidatedinaCVCbioﬁlminvivomodel[71].
The use of lock technique or preventive impregnation of
antifungals in combating catheter-associated infection seems
promising, but not yet convincing on a cost eﬀective point
of view as huge doses are still needed to eradicate fungal
growth.
3.2. Material Coating and Novel Antibioﬁlm Surfaces. Ad e -
veloping ﬁeld of research focuses on the usage of modiﬁed
materialsorcoatedsurfacestopreventadherenceandbioﬁlm
development. Implant materials are prone to bioﬁlm forma-
tionaﬀectinghealthingeneralanddurationoftheimplantin
particular. Surface characteristics, such as surface roughness,
surface free energy, and chemistry, can inﬂuence the type
and the feature of the bioﬁlms [114, 115]. For example, C.
albicans adhesion is enhanced if the roughness of the denture
materials is increased [116]. It is nowadays conceivable that
coatings may be engineered to promote selective adhesion,
with possible attachment to cell tissue (for implant in bone
contact) but not to microbes. They may also address the
second phase of bioﬁlm development involving quorum
sensing, by inhibiting cell-cell communication signals [117,
118]. Biomaterial modiﬁcations as a way to prevent bioﬁlm
development have been the focus of intense research, in
particular in the ﬁeld of bacterial bioﬁlms [119], but the
latest ﬁndings on their impact on Candida bioﬁlms are
discussed next.
3.2.1. Surface Modiﬁcations. Surface properties of medical
devices constitute a major factor contributing not only to
the stability in the body but also to their performance and
lifetime in vivo and their colonization by microorganisms.
In that matter, albumin adhesion is beneﬁcial since it has
been shown to prevent binding of microorganisms, while
ﬁbrinogen has the opposite eﬀect [120]. Chemical grafting
of polyethylene and polypropylene surfaces, functionalized
with cyclodextrins, yielded a change in protein adsorp-
tion proﬁle of these polymers, by promoting adsorption
of albumin and reducing adhesion of ﬁbrinogen to the
material surface[121]. In addition, these modiﬁed substrates
incorporated well the antifungal agent miconazole, leading
to reduced bioﬁlm formation by C. albicans in vitro.
Modiﬁedpolyethyleneandsiliconerubbersprovedtobevery
eﬃcient in inhibiting C. albicans bioﬁlm formation in vitro
[122]. These cytocompatible materials were also capable of
releasingforseveralhoursconsiderableamountofananionic
antimicrobial drug, nalidixic acid, suggesting their use as
drug-eluting systems.
Modiﬁcations of polyurethanes dental biomaterials by
addition of surface-modifying end groups were successfully
employed to manage C. albicans bioﬁlm formation [123].
In addition, correlation between contact angle and bioﬁlm
formation was surface dependent. Increased hydrophobicity
resulted in increased metabolic activity of the bioﬁlms
grown on polyetherurethane, while they inversely correlated
for bioﬁlms formed on polycarbonate surfaces. Addition
of 6% polyethylene oxide to Elastane 80A showed to be
the best combination as no bioﬁlm could be observed on
that surface. Bioﬁlms on voice prostheses consist of mixed
populations that can include C. albicans. Modiﬁcation of
the silicone surface of the prostheses has been employed to
limit C. albicans colonization, as opposed to incorporation
of antimicrobial agents in order to avoid the occurrence of
resistance [124]. Silicone disks grafted with C1 and C8 alkyl
side chains reduced adherence and bioﬁlm formation of C.
albicans by up to 92%. Longer side chains did not show as
good results, and combinations of quaternizing agents did
not work synergistically either. Similarly, grafting of cationic
peptides, such as the salivary peptide Hst5 and synthetic
variants,ontosiliconerubber,inhibitedbioﬁlmformationby
up to 93%, in a peptide-dependent manner [125].
3.2.2. Surface Coatings. Fungicidal or fungistatic materials
have been employed to fabricate or coat the surfaces of med-
ical devices and have a great potential in reducing or elim-
inating the incidence of bioﬁlm-related infections. Dental
resin material coated with thin-ﬁlm polymer formulations
containing the polyene antifungals nystatin, amphotericin B,
ortheantisepticagentchlorhexidine,wereusedinC.albicans
bioﬁlm assays [126]. Bioﬁlm reduction was the greatest
on chlorhexidine containing polymers, while the other
formulationsweremuchlesseﬃcient.Similarly,multilayered
polyelectrolyte thin ﬁlms containing an antifungal β-peptide
incorporated within the layers of the ﬁlms inhibited the
growth (and hyphal formation) of C. albicans by 74% after
2hofcontact[127].
The polysaccharide dextran is widely used in medicine
and is also one of the main components of dental plaque.
Cross-linked dextran disks soaked with amphotericin B
solutions, described as amphogel, kills fungi within 2 hours
of contact and can be reused for almost 2 months without
losing its eﬃcacy against C. albicans [128]. This antifungal
material is biocompatible and could be used to coat medical
devices to prevent microbial attachment. It was recently
used for local antifungal therapy in the form of injectable
cross-linking hydrogels [129]. Nitric oxide can antagonise
cell proliferation by signalling rather than by toxic eﬀect.
It regulates bacterial bioﬁlm dispersal and has also been
employed in releasing xerogel to attenuate C. albicans
adherence and bioﬁlm formation [130]. The nitric-oxide-
based method is still at the experimental level, due to poor
water solubility and stability.
Coating of medical material surfaces has been employed
and tested with several types of coating molecules, including
the naturally occurring polymer chitosan and antimicrobial
peptides such as Histatin 5 (Hst5). Surfaces coated with
the polymer reduced the viable cell number in bioﬁlms byInternational Journal of Microbiology 9
more than 95%, in the case of C. albicans and also for
many bacteria such as Staphylococcus aureus [131]. Chitosan,
which is proﬁcient against a wide range of pathogenic
microbes, disrupts cell membranes as cells settle on the
surface. The use of such polymer oﬀers a biocompatible
tool for further coating design of medical devices. Acrylic
disks precoated with Hst5 prove to be eﬃcient in inhibiting
bioﬁlm formation of C. albicans, especially in the later stage
ofdevelopment,whilebioﬁlmsensitivitytotheantimicrobial
peptide was the same as the one of free-living cells [132].
The utility and potential of selected peptides, as therapeutic
molecules, including the β-glucan synthesis inhibitors, the
histidine-rich peptides, and the LL-37 cathelicidin family are
being determined and could be used as coating compounds
against adherence and bioﬁlm formation [133, 134].
The possible applications of biomaterial modiﬁcation
remain to be clearly established and approved. Shift from a
commensal bacterial bioﬁlm to a more pathogenic bioﬁlm
involving Candida spp. in the oral cavity for instance is
believed to be more inﬂuenced by mucosal inﬂammation
and the general well-being of the host than on the nature
and surface properties of the material itself [135]. However,
development of materials that can fully abolish microbial
adherence is a promising perspective against bioﬁlm forma-
tion. The discrepancy between antimicrobial coatings killing
the bioﬁlm-proﬁcient organisms and antimicrobial releasing
coatings to prevent bioﬁlm formation is a current issue.
3.3. Quorum Sensing Molecules and Natural Byproducts.
Adhesion and bioﬁlm formation by C. albicans cells can
be modulated by physical and chemical signals from the
oral bacterium Streptococcus gordonii [91]. Indeed, most
Streptococcus species possess the antigen I/II, a cell-wall-
anchored protein receptor that mediates binding to C. albi-
cans.M o r e o v e r ,C. albicans hyphal and bioﬁlm development
are greatly enhanced by S. gordonii, which also relieved
the fungal cells from the repressing eﬀect of the quorum
sensing molecule farnesol [91]. Farnesol, a sesquiterpene
and signalling molecule produced by C. albicans, represses
bioﬁlm formation in vitro [136]. Conversely, tyrosol, a 2-
(4-hydroxyphenyl) ethanol derivative of tyrosine, accelerates
hypha production in the early stages of bioﬁlm development
and is secreted at least 50% more by bioﬁlm cells than by
planktonic cells [137]. Several studies demonstrated that
farnesol actually increases fungal pathogenicity in animal
models,potentiallybyinterferingwithnormalprogressionof
cytokine induction [138–140]. Analogs of farnesol have been
identiﬁed that fail to induce pathogenicity and yet retain
farnesol ability to block hyphal development [141]. While
these analogs did not protect mice from candidiasis, they
may be of interest in bioﬁlm inhibition. Indeed, a number of
moleculeswithfarnesol-likeactivity,thatcaninducetheshift
to the yeast form of growth, have been identiﬁed in Gram-
negative bacteria. For instance, the signalling molecule,
homoserine lactone, produced by Pseudomonas aeruginosa
represses C. albicans ﬁlamentation [142]. P. aeruginosa also
produces several phenazines that exhibit antifungal activity
againstC.albicans[143].Uptakeofthephenazinesgenerated
reactive oxygen species production and led to fungal cell
death. In mixed bioﬁlms, binding of the toxins to the fungal
cells has a negative inﬂuence on C. albicans growth.
In a diﬀerent approach, Valle et al. [144] demonstrated
that the use of nonantibiotic molecules, such as polysac-
charides, produced by competitive commensal organisms
can antagonize bioﬁlm formation. A better knowledge of
the microbial community behaviour and in particular of
theinteractionbetweencommensalandpathogenorganisms
would help to combat predominance of the infectious or
disease causative agents. In this scheme, natural products
produced by cells within a bioﬁlm contribute to the
dynamic of the community and may play an antiadhesion
role for nonwanted other microorganisms [145]. Bacterial
lipopolysaccharidesalsomodulateadhesionandbioﬁlmabil-
ity of several Candida species, in an interspecies-dependent
manner [146]. It is not known how mixed populations
aﬀect the host immune response in response to infection.
The overall population behaviour results from a potential
selective advantage to either or both species. While commu-
nication is the key, interpretation is the code. Identiﬁcation
andalterationsofthecommunicationsignalswouldcertainly
result in a better understanding of how species coexist
and permit a better control of bioﬁlm formation [147].
Targeting quorum sensing molecules or associated signalling
mechanisms is an open ﬁeld of research at present, but
the use of quorum quenching enzymes or quorum sensing
inhibitors naturally produced by other species could help in
the ﬁnding of novel antibioﬁlm agents [148, 149].
3.4. Host Responses to Bioﬁlms: Perspective of Immunotherapy.
With the number of people considered at high risk for
microbial infections constantly increasing, immunotherapy
seems to oﬀer a great potential despite the complexity of
the interaction between the host defence system and the
pathogen [150]. The ability of human pathogens, such as
Candida spp., to cause infections depends on a constant and
sometimes discontinuous battle between the pathogen and
the host immune system [151]. Recognition of Candida-
speciﬁc pathogen-associated molecular patterns (PAMPs) by
dedicated pattern recognition receptors (PRRs) such as Toll-
like receptors and lectins activates the innate eﬀector cells
(macrophages, dendritic cells, and neutrophils), which in
turn produce a variety of soluble factors, including cytokines
andchemokines[152].However,littleisyetknownaboutthe
interactions between human phagocytes and Candida spp.
bioﬁlms, while immunotherapeutic treatment against can-
didiasis has been undertaken [153, 154]. Chandra et al. [155]
demonstrated that adherent peripheral blood mononuclear
cells (PBMCs) enhanced the ability of C. albicans to form
bioﬁlm. They also observed that phagocytosis of the fungal
cells within a bioﬁlm did not occur while their free-
living counterparts were phagocytosed. These data deﬁned
the novel concept that Candida b i o ﬁ l m ss e e mt oh a v ea n
immunosuppressive eﬀect. Inactivated PBMCs on the other
hand did not induce this enhanced growth behaviour, nor
did lipopolysaccharide-activated PBMCs, suggesting that the
stimulated bioﬁlm formation resulted from (a) Candida-
bioﬁlm-induced secretory factor(s). Indeed, the cytokine
proﬁle of PBMCs following coculture with planktonic or10 International Journal of Microbiology
bioﬁlm cells of C. albicans diﬀered greatly, with IL-1β as
the cytokine most highly overexpressed by contact with
bioﬁlms. Supporting these data, a recent study showed that
phagocytesalone inducedmuch lessdamagetobioﬁlmsthan
they did to free-living cells or to resuspended bioﬁlm cells,
which lacked the overall structure of bioﬁlms and most of
the matrix [156]. Using confocal laser scanning microscopy,
Katragkou and coworkers deducted that human phagocytes
looked like unstimulated cells, presenting a rounded shape
when in presence of bioﬁlms. This was also conﬁrmed
by a reduced cytokine production in a bioﬁlm-phagocyte
coculture, compared to a planktonic cells-phagocytes mix.
Phagocytes appeared entrapped within the structured net-
work of cells and matrix and were unable to internalize cells
within bioﬁlms. Moreover, C. albicans and C. parapsilosis
bioﬁlmsweremoresusceptibletotheadditiveeﬀectsbetween
phagocytichostdefenceandtheechinocandinanidulafungin
than to each separately and to the combination of the
azole voriconazole with phagocytes [156, 157]. These data
validate the ﬁndings that echinocandins can inﬂuence host
cell interactions with bioﬁlm [158].
Pathogens have evolved many mechanisms of defence to
avoid being recognized by the host environment [159–161].
C. albicans can evade immune attack by masking its cell wall
β-glucan component, a potent pro-inﬂammatory signature
carbohydrate, under a thick layer of mannoproteins. Clear
evidence showed that exposing the β-glucans by treatment
with the antifungal drug caspofungin elicited a stronger
immune response [158]. These data suggest that echinocan-
din treatment may enhance immunity [162]. Masking of β-
glucans depends on a complex network of cell wall remod-
elling, and targeting these regulatory processes may identify
novel antifungal possibilities. For example, disruption of the
MAPK pathway regulated by the extracellular signal-induced
Cek1 kinase triggered a greater β-glucan exposure, which
resulted in an enhanced immune response compared to the
wild-type strain [163]. There are conﬂicting data regarding
the role of the β-glucan receptor Dectin-1, expressed widely
on phagocytes, in antifungal immunity [164]. However,
studies suggested that Dectin-1 is required for fungal killing
and induction of early inﬂammatory responses. These ﬁnd-
ings are of interest for bioﬁlm recognition by the immune
system, as β-1,3-glucans are found in high amounts in the
extracellular matrix of Candida bioﬁlms in vitro and in vivo
[10, 12, 165]. Bioﬁlms developed on soft tissue are associated
with inﬁltration of the infected sites by neutrophils, which
can then confer innate immune protection [166]. In C.
albicans, Hyr1, encoding a GPI-anchored cell wall protein,
has been shown to confer resistance to neutrophil killing
in vitro and in the oral mucosal tissue bioﬁlm model [12,
167]. In addition, vaccination with a recombinant Hyr1p
protected mice against hematogenously disseminated can-
didiasis. Immunotherapeutic strategies, such as vaccination,
anti-Candida antibodies, and cytokine therapy, are under
investigation to treat Candida infections [168]. However,
their applicability in treating bioﬁlm-related infections is
still in a preliminary state. In that framework, recent data
showed that pretreatment of C. albicans cells with antibodies
targeting the complement receptor 3-related protein led to
reduced adhesion and bioﬁlm formation in vitro [169]. In
another study, anti-C. albicans antibodies from chicken egg
yolk were employed as antiadherent molecules [170]. While
the adherence of C. albicans was reduced, bioﬁlm inhibition
was only observed in absence of serum, as the activity of
the antibody was very much reduced against germ tubes, of
which the formation is induced in the presence of serum.
In vivo studies of the antibody-based approach remain to be
investigated in the context of bioﬁlms.
4. Concluding Remarks
The large panel of bioﬁlm models suitable for Candida
researchhighlightsthediversityofnichesinwhichthefungus
candeveloprangingfrombiotictoabioticsurfaces.However,
the role and nature of host-pathogen interactions during
bioﬁlm formation are only starting to get unveiled. The
search for an antibioﬁlm treatment is a complex subject
which requires improved knowledge of the pathogen itself,
and also of the host response to adhesion and bioﬁlm for-
mation, the properties of the substrates onto which bioﬁlm
develop, and the interactions within microbial communities.
The ﬁeld of chemoinformatics may assist the development
of novel antibioﬁlm compounds, based on already identiﬁed
good candidate molecules [171]. This approach may also
reveal better coating agents for material surfaces that would
persist long periods of time in vivo. The use of natural
compounds, from dietary plants or probiotics, may also be
considered as they are better tolerated by humans.
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